onr:"swepub:oai:DiVA.org:uu-467399"
Sökning: onr:"swepub:oai:DiVA.org:uu-467399" > Population-based st...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
- Balabanova, YaninaBayer AG, Integrated Evidence Generat, D-13353 Berlin, Germany. (författare)
Population-based study of long-term anticoagulation for treatment and secondary prophylaxis of venous thromboembolism in men with prostate cancer in Sweden
- Artikel/kapitelEngelska2022
Förlag, utgivningsår, omfång ...
- 2022-02-02
- Springer Nature,2022
- electronicrdacarrier
Nummerbeteckningar
- LIBRIS-ID:oai:DiVA.org:uu-467399
- https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-467399URI
- https://doi.org/10.1186/s12894-022-00967-zDOI
Kompletterande språkuppgifter
- Språk:engelska
- Sammanfattning på:engelska
Ingår i deldatabas
- SwePubSwePub
Klassifikation
Anmärkningar
- BackgroundEpidemiological data on anticoagulation for venous thromboembolism (VTE) in prostate cancer are sparse. We aimed to investigate associations between anticoagulation duration and risks of VTE recurrence after treatment cessation and major on-treatment bleeding in men with prostate cancer in Sweden.MethodsUsing nationwide prostate cancer registry and prescribing data, we followed 1413 men with VTE and an outpatient anticoagulant prescription following prostate cancer diagnosis. Men were followed to identify cases of recurrent VTE, and hospitalized major bleeding. We calculated adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) to quantify the association between anticoagulation duration (reference <= 3 months) and recurrent VTE using Cox regression. We estimated 1-year cumulative incidences of major bleedings from anticoagulation initiation.ResultsThe outpatient anticoagulation prescribed was parenteral (64%), direct oral anticoagulant (31%), and vitamin K antagonist (20%). Median duration of anticoagulation was 7 months. Adjusted HRs (95% CI) for off-treatment recurrent pulmonary embolism (PE) were 0.32 (0.09-1.15) for > 3-6 months' duration, 0.21 (0.06-0.69) for > 6-9 months and 0.16 (0.05-0.55) for > 9 months; corresponding HRs for deep vein thrombosis (DVT) were 0.67 (0.27-1.66), 0.80 (0.31-2.07), and 1.19 (0.47-3.02). One-year cumulative incidences of intracranial, gastrointestinal and urogenital bleeding were 0.9%, 1.7%, 3.0% during treatment, and 1.2%, 0.9%, 1.6% after treatment cessation.ConclusionThe greatest possible benefit in reducing recurrent VTE risk occurred with > 9 months anticoagulation for PE and > 3-6 months for DVT, but larger studies are needed to confirm this. Risks of major bleeding were low overall.
Ämnesord och genrebeteckningar
- MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Hematologi hsv//swe
- MEDICAL AND HEALTH SCIENCES Clinical Medicine Hematology hsv//eng
- Anticoagulants
- Bleeding
- Prostate cancer
- Venous thromboembolism
Biuppslag (personer, institutioner, konferenser, titlar ...)
- Farahmand, BahmanBayer AB, Integrated Evidence Generat, Stockholm, Sweden. (författare)
- Stattin, PärUppsala universitet,Urologkirurgi(Swepub:uu)parst892 (författare)
- Garmo, HansUppsala universitet,Urologkirurgi(Swepub:uu)hanga600 (författare)
- Brobert, GunnarBayer AB, Integrated Evidence Generat, Stockholm, Sweden. (författare)
- Bayer AG, Integrated Evidence Generat, D-13353 Berlin, Germany.Bayer AB, Integrated Evidence Generat, Stockholm, Sweden. (creator_code:org_t)
Sammanhörande titlar
- Ingår i:BMC Urology: Springer Nature22:11471-2490
Internetlänk
- https://doi.org/10.1186/s12894-022-00967-zFulltext
- https://uu.diva-portal.org/smash/get/diva2:1638918/FULLTEXT01.pdffulltext:print
- https://bmcurol.biomedcentral.com/track/pdf/10.1186/s12894-022-00967-z
- https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-467399
- https://doi.org/10.1186/s12894-022-00967-z
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Balabanova, Yani ...
- Farahmand, Bahma ...
- Stattin, Pär
- Garmo, Hans
- Brobert, Gunnar
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Hematologi
- Artiklar i publikationen
- BMC Urology
- Av lärosätet
- Uppsala universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst. Hantera kakor
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
